U.S. Disposable Urology Devices Market: $8.96B by 2032

Market Outlook

By 2032, the U.S. Disposable Urology Devices Market is expected to reach approximately USD 8.96 billion, expanding at a CAGR of 9.78% during the forecast period 2027–2032. The market stood at USD 5.12 billion in 2026, following historical values of approximately USD 3.85 billion in 2023, USD 4.22 billion in 2024, and USD 4.64 billion in 2025. Values in this report are expressed in USD billions.

The U.S. disposable urology devices industry sits at the convergence of acute hospital surgical care, ambulatory endourology, infection prevention mandates, oncology diagnostics, and home urological continence management. Demand is underpinned by an expansive clinical burden encompassing urolithiasis, benign prostatic hyperplasia, bladder cancer, urinary incontinence, neurogenic bladder, pelvic floor disorders, and catheter-associated urinary tract infections. In 2024, over 12% of men and 6% of women in the United States were projected to experience a nephrolithiasis event during their lifetime, generating recurring surgical episodes that require single-use endoscopes, access sheaths, stone extraction baskets, and guidewires. Urological malignancies, notably urothelial carcinoma of the bladder, represent the sixth most common cancer in the United States, generating millions of routine surveillance cystoscopies that are transitioning from reusable fiberoptic and video towers to sterile single-use systems.

Catheterization represents a durable and volume-dense foundation within the urology device continuum. More than 4.5 million Americans rely on intermittent or indwelling catheterization annually due to spinal cord injuries, multiple sclerosis, spina bifida, diabetes-related neurogenic bladder, or acute perioperative retention. Catheter-associated urinary tract infections continue to represent the most prevalent form of hospital-acquired infection, accounting for over 15% of all healthcare-associated infections reported to the Centers for Disease Control and Prevention. Because acute inpatient facilities face direct financial penalties under the Centers for Medicare and Medicaid Services Hospital-Acquired Condition Reduction Program, health systems are rapidly migrating from conventional, non-coated catheters toward antimicrobial, closed-system, and advanced hydrophilic single-use intermittent catheters. This clinical priority generates continuous institutional and outpatient procurement volume.

Endourology creates a parallel high-growth, technology-intensive capital-to-consumable conversion. Conventional reusable flexible ureteroscopes and cystoscopes impose severe reprocessing friction, requiring complex multi-step enzymatic cleaning, high-level disinfection or low-temperature sterilization, routine scope maintenance, and frequent breakages. A standard reusable flexible ureteroscope typically requires professional servicing after every 8 to 15 surgical procedures, incurring repair expenses ranging from USD 0.003 billion to USD 0.008 billion per health system annually when fleet downtime and logistics are aggregated. Single-use digital flexible ureteroscopes, equipped with high-resolution complementary metal-oxide-semiconductor chips and light-emitting diode illumination, have eliminated scope-related cross-contamination risks while freeing operating room personnel from labor-intensive reprocessing workflows.

The market is simultaneously transitioning from acute hospital operating rooms toward ambulatory surgery centers and specialized office-based suites. Single-use technologies democratize procedural availability by removing the requirement for multi-million-dollar sterilization facilities and capital-intensive video towers. Ambulatory urology platforms, physician-led group practices, and independent surgical networks are rapidly acquiring sterile, out-of-the-box cystoscopes, laser fibers, and disposable biopsy forceps to manage kidney stone removals, stent exchanges, and tumor resections with accelerated turnover times. Manufacturers that integrate single-use visualization with ergonomic working channels, stone baskets, and integrated suction systems are establishing decisive competitive advantages.

The historical market expanded as U.S. hospital surgical volumes normalized, ambulatory procedure volumes surged, and infection control protocols heightened scrutiny around urological instrument bioburden. From 2027 onward, expansion is driven by the clinical adoption of disposable visualization platforms, the demographic expansion of the Medicare population, the mainstreaming of touch-free hydrophilic intermittent catheters, procedural migration to outpatient surgical facilities, and value-based hospital reimbursement penalties that reward single-use sterilization guarantees.

Introduction

According to the U.S. Disposable Urology Devices Market Report, disposable urology represents one of the most operationally dynamic sectors within the American medical device landscape because disposable products span high-volume personal drainage consumables to sophisticated single-use interventional surgical platforms. A patient navigating urological care may initially use single-use hydrophilic intermittent catheters in a home setting, undergo diagnostic cystoscopy via a single-use flexible scope in an outpatient physician office, receive ureteroscopic laser lithotripsy using single-use access sheaths and disposable digital ureteroscopes in an ambulatory surgical suite, and manage postoperative recovery through disposable double-J ureteral stents and closed drainage collection systems. This continuum unites high-velocity, recurring clinical consumables with high-margin interventional technologies.

Disposable urological consumables and surgical devices accounted for the entirety of this market, with urological catheters and disposable endoscopes representing the twin pillars of volume and value. Catheter systems represented approximately 42.8% of U.S. disposable urology device revenue in 2025, supported by the relentless demand for sterile intermittent catheters, closed-system drainage kits, Foley catheters, and external condom-style collection devices across acute and post-acute channels. Concurrently, disposable endoscopes represent the fastest-expanding technology tier, capturing roughly 22.4% of total market revenue in 2025 and shifting capital-intensive endourology into a predictable per-procedure consumable model.

Hospital and health system purchasing dynamics dictate the commercial velocity of disposable urology devices. While inpatient surgical suites and academic medical centers remain the primary buyers of advanced endourology disposables, ambulatory surgery centers are expanding their procurement footprint at double the rate of tertiary hospitals. The economic calculus governing urology procurement hinges on total cost of ownership, procedure room turnover velocity, instrument decontamination costs, occupational biohazard exposure, fleet downtime, and sterilization documentation compliance. For mid-sized community facilities and large health networks alike, adopting disposable platforms converts erratic capital expenditure and repair budgets into a variable, procedure-aligned operational expense.

Outpatient and home-based catheter distribution represents an entirely distinct commercial pathway governed by durable medical equipment channels, fee-for-service Medicare reimbursement, commercial payer fee schedules, and patient adherence workflows. Under Medicare Part B, beneficiaries with permanent urinary incontinence or retention who demonstrate appropriate clinical documentation qualify for up to 200 sterile single-use intermittent catheters per month under Healthcare Common Procedure Coding System billing codes. This reimbursement architecture has structurally accelerated the displacement of reusable, wash-and-reuse latex catheters by sterile, pre-lubricated, hydrophilic, and closed-system intermittent catheters designed to reduce mucosal trauma and micro-hematuria.

Regulatory vigilance from the Food and Drug Administration surrounding endoscope reprocessing has catalyzed institutional shifts toward single-use visualization. Successive safety alerts and surveillance mandates highlighting persistent microbiological bioburden on reprocessed duodenoscopes, bronchoscopes, and urological endoscopes have forced hospital infection control committees to audit reprocessing turnaround times and sterile processing department compliance. The documented risk of pathogen transmission, coupled with the labor costs of multi-tier chemical disinfection and ethylene oxide sterilization, has transformed disposable cystoscopes and ureteroscopes from experimental alternatives into frontline clinical standards across numerous U.S. healthcare systems.

From 2027 through 2032, leading medtech enterprises in the disposable urology ecosystem will compete through integrated end-to-end procedural systems. The preeminent suppliers will deliver complete procedural kits containing the single-use scope, guidewires, access sheaths, laser fibers, stone baskets, and post-procedural stents within a unified, barcoded, radio-frequency identified sterile package. By addressing the entire surgical workflow, manufacturers will minimize supply chain complexity for hospital materials management while shielding procedural economics from multi-vendor friction.

Key Market Drivers: What’s Fueling the U.S. Disposable Urology Devices Market Boom?

The foremost growth driver is the sheer demographic scale and epidemiological persistence of urolithiasis and benign prostatic hyperplasia across an aging American populace. Over 10% of the U.S. population experiences urinary stone disease, with recurrence rates approaching 50% within ten years of the initial stone event. This recurring pathology generates more than 1.3 million emergency department visits and hundreds of thousands of ureteroscopic stone fragmentation procedures annually. Benign prostatic hyperplasia affects more than 50% of American men aged 51 to 60 and up to 90% of men over 80 years old, resulting in severe lower urinary tract symptoms, acute urinary retention, and routine catheter interventions. These chronic degenerative pathologies ensure an expanding baseline of surgical interventions and catheterizations.

A second major catalyst is the relentless clinical and economic war against Catheter-Associated Urinary Tract Infections across American health systems. The Centers for Medicare and Medicaid Services does not reimburse hospitals for the incremental costs incurred when managing hospital-acquired infections, including CAUTIs, under the Inpatient Prospective Payment System. Furthermore, hospitals ranking in the worst-performing quartile under the Hospital-Acquired Condition Reduction Program face a mandatory 1% reduction in total Medicare inpatient payments across all admissions. Because a single CAUTI episode introduces an estimated USD 0.013 billion to USD 0.028 billion in unreimbursed hospital expenditures across an extended patient stay, clinical leadership has aggressively transitioned from open, non-coated indwelling catheters toward closed-system pre-connected Foley trays, antimicrobial silver-hydrogel coatings, and single-use touch-free intermittent catheter systems.

A third driver is the rapid procedural migration of endourology into Ambulatory Surgery Centers and office-based laboratories. Driven by commercial payer incentives, Medicare ambulatory payment classification expansions, and hospital capacity constraints, urologists are shifting routine diagnostic cystoscopies, stent removals, and uncomplicated stone management cases into outpatient environments. ASCs operate on lean staffing models and frequently lack the capital reserves to install centralized sterile processing departments, vaporized hydrogen peroxide sterilizers, and extensive scope inventory. Disposable cystoscopes, single-use ureteroscopes, and pre-packaged lithotripsy disposables allow ASCs to eliminate reprocessing infrastructure entirely, achieve twelve-minute room turnovers, and expand daily surgical capacity.

A fourth driver is the technological maturation of single-use digital visualization systems. Early disposable endoscopes suffered from inferior optical resolution, restricted deflection angles, and substandard working-channel stiffness relative to premium reusable platforms. Modern single-use ureteroscopes and cystoscopes incorporate sub-millimeter complementary metal-oxide-semiconductor image sensors, integrated dual-light-emitting diodes, 270-degree bidirectional active deflection, and specialized working channels that comfortably accommodate holmium and thulium fiber laser delivery systems without compromising irrigation flow. Urologists are no longer forced to compromise optical performance for convenience, leading to widespread institutional adoption.

A fifth driver is the elimination of scope downtime, repair volatility, and inventory management complexity. In high-volume endourology practices, reusable flexible scopes break with notorious regularity when working tools such as laser fibers or nitinol baskets are articulated within deflected shafts. In-house processing delays and third-party scope servicing typically keep 20% to 30% of a hospital’s reusable flexible scope fleet out of service at any given moment. Disposable platforms eliminate repair budgets, simplify hospital capital planning, and ensure that every patient intervention is conducted with a pristine, factory-calibrated device that exhibits zero performance degradation from prior use.

A sixth driver is the expansion of favorable Medicare Part B reimbursement policies for advanced home continence consumables. The continuous codification of coverage criteria for no-touch, pre-lubricated, and hydrophilic intermittent catheters has shifted chronic urinary retention management away from reusable wash-and-dry rubber catheters, which carry elevated risks of urethral strictures, bleeding, and recurring infections. As home healthcare agencies and durable medical equipment distributors leverage digital re-ordering portals and automated patient compliance platforms, adherence to prescribed single-use catheter regimens has escalated, solidifying a stable, high-volume recurring market.

Finally, supply chain consolidation and environmental lifecycle improvements are accelerating institutional conversion. Leading manufacturers are establishing closed-loop collection, recycling, and medical-grade incineration programs that mitigate hospital concerns regarding single-use plastic waste. Concurrently, Group Purchasing Organizations and Integrated Delivery Networks are negotiating comprehensive enterprise contracts that tie disposable endoscopes, access sheaths, guidewires, stents, and surgical suction disposables into unified, tiered pricing matrices, locking in long-term supply commitments across national hospital networks.

Innovation in Focus: How Manufacturers Are Raising the Bar?

Innovation across the U.S. disposable urology device sector has shifted away from basic single-use plastic replication toward precision engineering, advanced biomaterials, embedded electronics, and complete procedure-specific workflow integrations. Medtech engineering teams are optimizing every millimeter of device architecture to solve specific clinical bottlenecks, ranging from mucosal friction during catheterization to working-channel irrigation dynamics during laser lithotripsy.

Within disposable visualization, the frontier of innovation centers on sensor-in-tip miniaturization, optical enhancement algorithms, and ergonomic handle design. Contemporary single-use flexible ureteroscopes are integrating high-definition complementary metal-oxide-semiconductor sensors with advanced digital signal processors that automatically compensate for turbulent irrigation fluid, blood dispersion, and thermal flare from holmium and thulium lasers. Proprietary image processing software provides high-contrast visualization modes that highlight mucosal vascularity to assist in early-stage urothelial carcinoma detection during diagnostic cystoscopy. Furthermore, manufacturers are constructing shafts using multi-durometer polymer extrusion and braided stainless-steel meshes, ensuring the torsional stiffness and column strength of a disposable scope perfectly mimic the tactile feedback of high-end reusable instruments.

Another breakthrough domain is integrated intracorporeal suction within disposable ureteroscopy platforms. In conventional stone management, lithotripsy generates stone dust and micro-fragments that obscure the optical field, elevate intrarenal pressure, and risk infectious pyelovenous backflow or postoperative sepsis. Next-generation single-use ureteroscopes feature dedicated integrated suction channels and pressure-sensing tips that dynamically evacuate irrigation fluid and stone dust in real time. By keeping intrarenal pressures below the critical threshold of 30 millimeters of mercury, these devices reduce the incidence of postoperative systemic inflammatory response syndrome and eliminate the need for secondary stone retrieval passes.

In the catheter domain, material science innovation focuses on hyper-hydrophilic surface modifications, bio-inspired lubricity, and antimicrobial coatings. Advanced intermittent catheters employ cross-linked polyvinylpyrrolidone polymers chemically grafted to the catheter substrate, creating an isotropic water-binding hydrogel layer that maintains an ultra-low coefficient of friction throughout insertion and withdrawal. This eliminates micro-abrasions in the urethral mucosa, reducing the incidence of traumatic strictures in lifetime catheter users. Furthermore, closed-system catheter kits now integrate touch-free guide sleeves, pre-lubricated insertion tips, and sterile collection bags, allowing immunocompromised patients or individuals with limited manual dexterity to perform aseptic self-catheterization without touching the catheter tube directly.

Ureteral stent innovation is addressing the longstanding challenge of stent-associated encrustation, biofilm formation, and patient discomfort. Traditional polymer stents induce significant trigone irritation and flank pain, while encrustation can complicate stent extraction. Modern single-use double-J stents are utilizing proprietary thermo-expandable and biodurable aliphatic polyurethane compounds, fluoropolymer coatings, and hydrophilic surface treatments that repel protein absorption and inhibit bacterial adhesion. Novel magnetic-tipped disposable stents, combined with dedicated single-use magnetic retrieval catheters, permit non-invasive in-office stent removal without the need for secondary cystoscopy, sparing patients pain and slashing clinical overhead.

Nitinol metallurgy and stone basket geometry have experienced parallel evolutionary strides. Single-use stone retrieval baskets and anti-retropulsion devices employ multi-wire, tipless superelastic nitinol configurations capable of capturing calyceal stones as small as 1 millimeter without puncturing delicate renal parenchyma. These single-use baskets feature specialized torque-stable sheaths that allow 360-degree rotational control within tight infundibula, enabling urologists to navigate tortuous upper urinary tract anatomy with confidence.

Digital connectivity and inventory automation are transforming how disposables are managed in the hospital ecosystem. Manufacturers are equipping single-use urology packaging with near-field communication chips and barcoding compatible with hospital enterprise resource planning platforms. When a single-use ureteroscope or catheter tray is unboxed in the procedural suite, procedural data, lot tracking, expiration verification, and patient billing codes are automatically uploaded to the hospital electronic medical record, eliminating documentation errors, preventing the use of expired inventory, and optimizing just-in-time replenishment.

Segmentation Insights

The U.S. Disposable Urology Devices Market is segmented on the basis of Product Type, Clinical Indication, End User, Technology and Material, Procedure Type, and Geography.

By Product Type

The U.S. Disposable Urology Devices Market is categorized by product type into Disposable Urological Endoscopes, Urological Catheters, Ureteral Stents and Retrieval Devices, Stone Management Disposables, and Urodynamic and Biopsy Disposables.

Disposable Urological Endoscopes
Disposable urological endoscopes generated USD 1.15 billion in 2026, building upon historical totals of USD 0.78 billion in 2023, USD 0.89 billion in 2024, and USD 1.01 billion in 2025, and are projected to reach USD 2.38 billion by 2032, expanding at a CAGR of 12.89% from 2027 to 2032. This segment encompasses single-use flexible ureteroscopes, single-use flexible cystoscopes, and specialized disposable nephroscopes. Growth is propelled by institutional mandates to eliminate scope-related microbiological contamination, bypass expensive service contracts, and accommodate high-volume stone and diagnostic workflows across hospital suites and outpatient surgery centers. The transition toward high-definition chip-on-tip visual sensors and integrated vacuum suction channels ensures that single-use endoscopes achieve diagnostic and therapeutic equivalency with legacy reusable platforms while slashing per-procedure room turnaround times.

Urological Catheters
Urological catheters generated USD 2.14 billion in 2026, following historical values of USD 1.71 billion in 2023, USD 1.84 billion in 2024, and USD 1.98 billion in 2025, and are forecast to reach USD 3.39 billion by 2032, reflecting a CAGR of 7.97% from 2027 to 2032. This category comprises intermittent catheters, indwelling Foley catheters, and external condom-style collection devices. Intermittent catheters represent the primary revenue engine within this segment, fueled by rising spinal cord injury survivorship, multiple sclerosis prevalence, and expanding Medicare Part B reimbursement for touch-free hydrophilic variants. Indwelling catheter lines are shifting away from traditional latex toward 100% silicone closed-system kits with antimicrobial silver-hydrogel coatings designed to curb catheter-associated urinary tract infections across inpatient intensive care and step-down units.

Ureteral Stents and Retrieval Devices
Ureteral stents and retrieval devices accounted for USD 0.72 billion in 2026, having recorded USD 0.56 billion in 2023, USD 0.61 billion in 2024, and USD 0.66 billion in 2025, and are slated to attain USD 1.21 billion by 2032, registering an 8.99% CAGR from 2027 to 2032. Double-J ureteral stents, tipless nitinol extraction baskets, guidewires, and magnetic retrieval devices form the core of this segment. These disposable components are indispensable in maintaining ureteral patency following lithotripsy, relieving malignant extrinsic obstructions, and extracting calculus fragments. The development of hydrophilic-coated polyurethane stents that minimize encrustation and bladder trigone irritation, alongside magnetic-tipped extraction catheters that permit rapid office-based stent removal without secondary cystoscopy, continues to stimulate clinical utilization.

Stone Management Disposables
Stone management disposables registered USD 0.67 billion in 2026, moving from USD 0.49 billion in 2023, USD 0.54 billion in 2024, and USD 0.60 billion in 2025, and are expected to achieve USD 1.18 billion by 2032, advancing at a CAGR of 9.94% from 2027 to 2032. This group includes disposable ureteral access sheaths, single-use holmium and thulium laser fibers, lithotripsy balloons, anti-retropulsion devices, and disposable stone evacuation filters. Heightened prevalence of kidney stone disease, coupled with the widespread adoption of dusting lithotripsy techniques, has intensified demand for high-durability access sheaths that withstand repetitive scope insertions while maintaining low continuous intrarenal pressures through passive or active outflow channels.

Urodynamic and Biopsy Disposables
Urodynamic and biopsy disposables represented USD 0.44 billion in 2026, advancing from USD 0.31 billion in 2023, USD 0.34 billion in 2024, and USD 0.39 billion in 2025, and are anticipated to reach USD 0.80 billion by 2032, exhibiting a CAGR of 10.49% from 2027 to 2032. The segment includes single-use urodynamic pressure catheters, air-charged and water-filled transducer lines, disposable EMG needle electrodes, and sterile prostate biopsy needles. Demand is driven by demographic aging, comprehensive diagnostic workups for refractory overactive bladder and stress urinary incontinence, and expanding surveillance biopsies for prostate and urothelial neoplasms conducted in specialized ambulatory urology clinics.

By Clinical Indication

The U.S. Disposable Urology Devices Market is segmented by clinical indication into Urolithiasis and Kidney Stones, Urinary Incontinence and Pelvic Organ Prolapse, Benign Prostatic Hyperplasia, Urological Cancers, and Neurogenic Bladder and Spinal Cord Injury.

Urolithiasis and Kidney Stones
Urolithiasis and kidney stones generated USD 1.69 billion in 2026, following historical marks of USD 1.23 billion in 2023, USD 1.36 billion in 2024, and USD 1.52 billion in 2025, and are projected to attain USD 3.09 billion by 2032, charting a CAGR of 10.58% from 2027 to 2032. The staggering incidence of renal and ureteral calculi in the American population, accelerated by metabolic syndrome, high dietary sodium, and climate-induced dehydration, creates sustained procedural volumes. Disposable ureteroscopes, ureteral access sheaths, single-use laser fibers, nitinol retrieval baskets, and temporary post-procedural stents are heavily utilized during retrograde intrarenal surgeries, ensuring this clinical indication maintains the largest share of disposable interventional expenditure.

Urinary Incontinence and Pelvic Organ Prolapse
Urinary incontinence and pelvic organ prolapse accounted for USD 1.28 billion in 2026, having recorded USD 0.99 billion in 2023, USD 1.08 billion in 2024, and USD 1.18 billion in 2025, and are projected to reach USD 2.15 billion by 2032, expanding at an 8.99% CAGR from 2027 to 2032. Affecting more than 25 million adult Americans, primarily women and older demographics, urinary incontinence drives continuous utilization of disposable diagnostic urodynamic lines, sterile intermittent catheters, and external continence management devices. Clinical protocols favoring early, non-surgical intervention and hygienic home-based self-catheterization regimens reinforce steady consumable volume expansion across this clinical category.

Benign Prostatic Hyperplasia
Benign prostatic hyperplasia represented USD 0.87 billion in 2026, moving from USD 0.66 billion in 2023, USD 0.72 billion in 2024, and USD 0.79 billion in 2025, and is expected to climb to USD 1.50 billion by 2032, advancing at a CAGR of 9.49% from 2027 to 2032. With millions of aging males experiencing progressive bladder outlet obstruction, clinical management relies heavily on disposable intermittent and indwelling Foley catheters to relieve acute urinary retention. Furthermore, the rapid growth of minimally invasive BPH surgical therapies and office-based transurethral interventions requires single-use cystoscopic delivery systems, customized disposable irrigation circuits, and specialized post-resection drainage products.

Urological Cancers
Urological cancers generated USD 0.77 billion in 2026, after recording USD 0.57 billion in 2023, USD 0.63 billion in 2024, and USD 0.70 billion in 2025, and are forecast to reach USD 1.39 billion by 2032, registering a CAGR of 10.34% from 2027 to 2032. Bladder cancer surveillance represents an exceptionally scope-intensive clinical pathway due to high tumor recurrence rates requiring quarterly or semi-annual flexible cystoscopies for life. Single-use cystoscopes, disposable biopsy forceps, cytology brushes, and post-instillation chemo-resistant catheters drive steady market expansion across hospital outpatient departments and regional oncology networks.

Neurogenic Bladder and Spinal Cord Injury
Neurogenic bladder and spinal cord injury accounted for USD 0.51 billion in 2026, having expanded from USD 0.40 billion in 2023, USD 0.43 billion in 2024, and USD 0.45 billion in 2025, and are projected to attain USD 0.83 billion by 2032, exhibiting an 8.46% CAGR from 2027 to 2032. Individuals living with traumatic spinal injuries, multiple sclerosis, transverse myelitis, and spina bifida lack normal detrusor control, requiring life-long, routine clean intermittent catheterization up to four to six times per day. The critical necessity of avoiding recurrent urinary tract infections, urethral strictures, and renal deterioration ensures that patients and caregivers consistently utilize premium, pre-lubricated hydrophilic catheters and sterile closed-system kits.

By End User

The U.S. Disposable Urology Devices Market is segmented by end user into Hospitals and Integrated Health Networks, Ambulatory Surgery Centers, Outpatient Urological Clinics and Physician Offices, and Home Healthcare and Long-Term Care Facilities.

Hospitals and Integrated Health Networks
Hospitals and integrated health networks generated USD 2.35 billion in 2026, based on historical marks of USD 1.83 billion in 2023, USD 1.98 billion in 2024, and USD 2.16 billion in 2025, and are anticipated to attain USD 3.96 billion by 2032, recording an 8.99% CAGR from 2027 to 2032. Hospitals remain the preeminent purchasers of advanced disposable urology systems, consuming high volumes of single-use ureteroscopes, closed-system Foley catheter trays, ureteral access sheaths, and laser fibers across intensive care units, emergency trauma suites, and inpatient surgical theaters. Enterprise purchasing committees leverage group purchasing agreements to standardize disposable fleets, mitigating contamination hazards and eliminating sterile processing bottlenecks across regional hospital campuses.

Ambulatory Surgery Centers
Ambulatory surgery centers represented USD 1.28 billion in 2026, having grown from USD 0.88 billion in 2023, USD 0.99 billion in 2024, and USD 1.12 billion in 2025, and are projected to surge to USD 2.47 billion by 2032, tracking a brisk CAGR of 11.58% from 2027 to 2032. ASCs represent the fastest-expanding surgical end-user tier. Operating on highly streamlined operating schedules, ambulatory facilities prioritize single-use endourology consumables to bypass the substantial capital investment and physical footprint demanded by centralized sterile processing departments. The rapid migration of outpatient ureteroscopy, retrograde stone management, and bladder tumor resections into ASCs fuels outsized commercial demand for sterile, procedure-ready disposable procedural packs.

Outpatient Urological Clinics and Physician Offices
Outpatient urological clinics and physician offices accounted for USD 0.82 billion in 2026, following historical figures of USD 0.60 billion in 2023, USD 0.66 billion in 2024, and USD 0.74 billion in 2025, and are forecast to reach USD 1.49 billion by 2032, registering a CAGR of 10.47% from 2027 to 2032. Independent urology group practices rely extensively on single-use cystoscopes for routine diagnostic evaluations, surveillance of urothelial tumors, and double-J stent extractions. Disposable visualization removes the logistical friction of chemical soaking and disinfection between patients, enabling clinics to expand patient throughput and procedural scheduling within standard examination rooms.

Home Healthcare and Long-Term Care Facilities
Home healthcare and long-term care facilities accounted for USD 0.67 billion in 2026, building upon USD 0.54 billion in 2023, USD 0.59 billion in 2024, and USD 0.62 billion in 2025, and are expected to achieve USD 1.04 billion by 2032, registering a 7.60% CAGR from 2027 to 2032. Skilled nursing facilities, assisted living centers, and home health agencies handle millions of catheterizations annually. Driven by Medicare Part B reimbursement guidelines and infection control oversight from state regulatory bodies, long-term care environments are replacing unhygienic reusable catheters with packaged, sterile hydrophilic intermittent catheters and secure closed-system drainage bags to minimize institutional bacteremia outbreaks.

By Technology and Material

The U.S. Disposable Urology Devices Market is segmented by technology and material into Hydrophilic and Pre-Lubricated Coated Polymers, Silicone and Elastomeric Formulations, Polyurethane and Specialized Copolymers, and Digital Visualization and CMOS Platforms.

Hydrophilic and Pre-Lubricated Coated Polymers
Hydrophilic and pre-lubricated coated polymers generated USD 1.89 billion in 2026, following historical figures of USD 1.48 billion in 2023, USD 1.60 billion in 2024, and USD 1.74 billion in 2025, and are slated to attain USD 3.19 billion by 2032, achieving a CAGR of 9.11% from 2027 to 2032. This technology segment underpins advanced intermittent catheters and high-performance guidewires. Hydrophilic polymer coatings chemically bind water molecules to create an ultra-slick, non-abrasive surface that remains stable throughout insertion and extraction. Clinical evidence confirming reductions in urethral trauma, micro-hematuria, and catheter-induced discomfort drives strong adoption among both chronic self-catheterizing patients and acute hospital clinical staff.

Silicone and Elastomeric Formulations
Silicone and elastomeric formulations accounted for USD 1.23 billion in 2026, having recorded USD 1.01 billion in 2023, USD 1.08 billion in 2024, and USD 1.15 billion in 2025, and are forecast to reach USD 1.89 billion by 2032, exhibiting a 7.42% CAGR from 2027 to 2032. All-silicone formulations dominate indwelling Foley catheter production and external collection systems. The biological inertness of medical-grade silicone minimizes mucosal inflammation, resists encrustation, and eliminates latex allergic reactions among patients and healthcare workers. Inpatient infection control protocols heavily prioritize 100% silicone closed drainage systems for long-term catheterization in critical care and geriatric wards.

Polyurethane and Specialized Copolymers
Polyurethane and specialized copolymers registered USD 1.05 billion in 2026, advancing from USD 0.77 billion in 2023, USD 0.85 billion in 2024, and USD 0.94 billion in 2025, and are expected to achieve USD 1.95 billion by 2032, charting a CAGR of 10.87% from 2027 to 2032. Polyurethane is the foundational material for ureteral access sheaths, double-J stents, and the braided shafts of disposable endoscopes. Engineered to soften at human body temperature while retaining exceptional radial tensile strength, these copolymers resist collapse during continuous intracorporeal irrigation, provide torsional stability for endoscopic navigation, and maintain lumen patency during prolonged upper tract urinary drainage.

Digital Visualization and CMOS Platforms
Digital visualization and CMOS platforms stood at USD 0.95 billion in 2026, progressing from USD 0.59 billion in 2023, USD 0.69 billion in 2024, and USD 0.81 billion in 2025, and are anticipated to attain USD 1.93 billion by 2032, expanding at an aggressive CAGR of 12.53% from 2027 to 2032. This technology group encompasses the micro-optical sensors, integrated light-emitting diodes, digital image signal processors, and companion monitor interfaces that power modern single-use cystoscopes and ureteroscopes. Advancements in sub-millimeter CMOS sensor fabrication and high-efficiency image transmission algorithms deliver crystal-clear resolution directly to compact displays, liberating surgical suites from expensive capital towers while maintaining uncompromised visualization.

By Procedure Type

The U.S. Disposable Urology Devices Market is segmented by procedure type into Diagnostic Endoscopy and Biopsy, Therapeutic Stone Removal and Lithotripsy, Urethral and Bladder Drainage Procedures, and Reconstructive and Oncological Urological Procedures.

Diagnostic Endoscopy and Biopsy
Diagnostic endoscopy and biopsy generated USD 1.23 billion in 2026, building upon historical values of USD 0.88 billion in 2023, USD 0.98 billion in 2024, and USD 1.10 billion in 2025, and are projected to reach USD 2.37 billion by 2032, representing a CAGR of 11.55% from 2027 to 2032. The vast volume of diagnostic cystoscopies performed for hematuria evaluation, recurrent urinary tract infection workups, and bladder cancer surveillance drives this procedure category. The transition from legacy reusable scopes to sterile, disposable cystoscopes and single-use biopsy forceps allows urologists to conduct diagnostic evaluations rapidly across outpatient clinics without scheduling constraints or infection control concerns.

Therapeutic Stone Removal and Lithotripsy
Therapeutic stone removal and lithotripsy accounted for USD 1.48 billion in 2026, after recording USD 1.06 billion in 2023, USD 1.18 billion in 2024, and USD 1.32 billion in 2025, and are anticipated to climb to USD 2.76 billion by 2032, tracking a CAGR of 10.94% from 2027 to 2032. Retrograde intrarenal surgery, ureteroscopic stone fragmentation, and percutaneous nephrolithotomy demand a comprehensive suite of single-use devices for every surgical episode. A standard procedure utilizes a disposable digital ureteroscope, access sheath, laser fiber, tipless nitinol stone basket, guidewires, and a postoperative double-J stent, consolidating this segment as a primary engine of interventional revenue.

Urethral and Bladder Drainage Procedures
Urethral and bladder drainage procedures represented USD 1.74 billion in 2026, following historical amounts of USD 1.42 billion in 2023, USD 1.52 billion in 2024, and USD 1.63 billion in 2025, and are forecast to reach USD 2.65 billion by 2032, registering a 7.28% CAGR from 2027 to 2032. This volume-intensive category encompasses acute perioperative bladder decompression, routine management of chronic urinary retention, and emergency catheterization in intensive care units. The clinical emphasis on CAUTI reduction in institutional settings and the daily requirements of chronic intermittent self-catheterization ensure high, recurring consumable volumes.

Reconstructive and Oncological Urological Procedures
Reconstructive and oncological urological procedures registered USD 0.67 billion in 2026, expanding from USD 0.49 billion in 2023, USD 0.54 billion in 2024, and USD 0.59 billion in 2025, and are projected to attain USD 1.18 billion by 2032, recording an 9.91% CAGR from 2027 to 2032. Encompassing complex surgical interventions such as transurethral resection of bladder tumors, radical prostatectomy post-surgical drainage, ureteral stricture dilations, and pelvic reconstruction, this segment utilizes specialized single-use guidewires, dilation balloons, high-flow irrigation sets, chemo-resistant instillation catheters, and long-term biodurable ureteral stents.

Regional Insights: Where the Market is Growing Fastest

The U.S. Disposable Urology Devices Market is geographically segmented into the South, Northeast, Midwest, and West. Regional demand varies considerably based on population demographics, nephrolithiasis prevalence, age distribution, hospital density, ambulatory surgery center expansion, Medicare reimbursement penetration, specialist availability, and state-level healthcare procurement dynamics.

South

The South represents the largest and most commercially lucrative region within the U.S. disposable urology device industry, generating USD 1.98 billion in 2026, following historical figures of USD 1.48 billion in 2023, USD 1.63 billion in 2024, and USD 1.80 billion in 2025, and is projected to expand at a CAGR of 9.91% to reach USD 3.49 billion by 2032. This commercial prominence is anchored by a vast and rapidly growing population base, an exceptionally high concentration of Medicare beneficiaries, expansive healthcare delivery networks, and the geographical phenomenon known as the Stone Belt. Across the Southeastern states, elevated average temperatures and dietary patterns correlate with higher rates of dehydration, resulting in a diagnosed nephrolithiasis prevalence that is roughly 25% higher than in other regions of the country. This elevated stone burden translates directly into surging procedural volumes for ureteroscopy, retrograde stone removal, single-use access sheaths, laser fibers, and postoperative double-J stents.

Texas stands as a premier pillar of urological device consumption in the United States, generating USD 0.58 billion in 2026, having recorded USD 0.43 billion in 2023, USD 0.48 billion in 2024, and USD 0.53 billion in 2025, and is forecast to achieve USD 1.04 billion by 2032, expanding at a CAGR of 10.22% from 2027 to 2032. Texas features an immense healthcare infrastructure anchored by the Texas Medical Center in Houston, major health networks across Dallas-Fort Worth, and expansive hospital systems throughout San Antonio and Austin. The state’s large industrial, agricultural, and urban workforces, combined with high ambient heat and metabolic syndrome rates, generate exceptionally dense kidney stone treatment pipelines. Furthermore, Texas has emerged as one of the nation’s leading battlegrounds for ambulatory surgery center development, where independent urology groups are establishing outpatient procedural suites that utilize single-use cystoscopes and disposable ureteroscopes to accelerate case turnover.

Florida represents another critical commercial stronghold, accounting for USD 0.51 billion in 2026, having grown from USD 0.39 billion in 2023, USD 0.43 billion in 2024, and USD 0.47 billion in 2025, and is expected to climb to USD 0.89 billion by 2032, reflecting a 9.73% CAGR from 2027 to 2032. Florida’s market dynamics are uniquely defined by its substantial retirement population, where over 21% of residents are aged 65 or older. This demographic profile produces high clinical demand for benign prostatic hyperplasia interventions, urinary incontinence management, bladder cancer surveillance, and chronic catheterization for neurogenic bladder. Senior living communities, skilled nursing centers, and home health agencies throughout Tampa, Orlando, Miami, and Jacksonville drive intense recurring orders for closed-system Foley catheter trays and sterile hydrophilic intermittent catheters. In hospital settings, Florida health systems maintain aggressive infection control policies to avoid CMS penalties, reinforcing the complete transition to antimicrobial single-use catheter systems.

North Carolina generated USD 0.21 billion in 2026, building upon historical values of USD 0.16 billion in 2023, USD 0.17 billion in 2024, and USD 0.19 billion in 2025, and is slated to attain USD 0.37 billion by 2032, registering a CAGR of 9.94% from 2027 to 2032. The state benefits from world-class academic health systems, including Duke University Health System, UNC Health, and Atrium Health, which serve as early evaluators and adopters of innovative single-use surgical visualization platforms. The state’s suburban and rural communities exhibit elevated urolithiasis rates, sustaining steady demand for disposable stone management kits.

Georgia accounted for USD 0.20 billion in 2026, having recorded USD 0.15 billion in 2023, USD 0.16 billion in 2024, and USD 0.18 billion in 2025, and is projected to reach USD 0.35 billion by 2032, achieving a CAGR of 9.78% from 2027 to 2032. The metropolitan Atlanta market, home to major hospital systems such as Piedmont Healthcare and Emory Healthcare, serves as a major hub for advanced endourology procedures. Outside the metropolitan core, rural Georgia health systems prioritize single-use endoscopes to bypass the capital cost of installing specialized reprocessing suites in low-volume community hospitals.

Virginia generated USD 0.16 billion in 2026, moving from USD 0.12 billion in 2023, USD 0.13 billion in 2024, and USD 0.14 billion in 2025, and is anticipated to reach USD 0.28 billion by 2032, charting a 9.79% CAGR from 2027 to 2032. Virginia features large integrated delivery networks, such as Inova Health System and Sentara Healthcare, that leverage centralized procurement models to secure high-volume supply contracts for sterile catheter trays, single-use cystoscopes, and urodynamic testing disposables.

Tennessee, Louisiana, Oklahoma, and West Virginia collectively contributed USD 0.32 billion in 2026, having advanced from USD 0.23 billion in 2023, USD 0.26 billion in 2024, and USD 0.29 billion in 2025, and are forecast to reach USD 0.56 billion by 2032, expanding at a CAGR of 9.78% from 2027 to 2032. These states exhibit high chronic disease burdens, elevated smoking rates contributing to bladder cancer incidence, and pervasive stone disease. In West Virginia and rural Oklahoma, where geographic dispersion restricts access to tertiary sterilization hubs, disposable endoscopes provide community urologists with immediate procedural readiness without scope transport logistics.

West

The West represents the fastest-growing disposable urology device market in the United States, generating USD 1.21 billion in 2026, building upon historical values of USD 0.88 billion in 2023, USD 0.98 billion in 2024, and USD 1.09 billion in 2025, and is projected to surge to USD 2.22 billion by 2032, expanding at an aggressive CAGR of 10.64% from 2027 to 2032. This outsized growth trajectory is powered by rapid population growth across the Mountain West and Pacific regions, a high density of progressive integrated health networks, early regulatory and clinical enthusiasm for single-use medical technologies, and the rapid deployment of ambulatory surgical suites. Healthcare systems throughout the West prioritize procedural efficiency, digital operating room integration, and staff safety, making them ideal launchpads for next-generation single-use ureteroscopy platforms with integrated suction and cloud-enabled digital imaging.

California dominates the regional market and stands as the single largest state urology market in the nation, generating USD 0.62 billion in 2026, after recording USD 0.46 billion in 2023, USD 0.51 billion in 2024, and USD 0.56 billion in 2025, and is forecast to achieve USD 1.15 billion by 2032, tracking a brisk CAGR of 10.87% from 2027 to 2032. California’s market scale is propelled by massive integrated delivery networks such as Kaiser Permanente, Sutter Health, and the University of California Health system. Kaiser Permanente has pioneered enterprise-wide infection prevention protocols, standardizing on single-use flexible cystoscopy across hundreds of outpatient clinics to eliminate scope cross-contamination risks and optimize clinical staffing. Furthermore, Southern California metropolitan centers, including Los Angeles, Orange County, and San Diego, feature the nation’s highest concentration of outpatient surgery centers and private urology practices, creating intense recurring demand for disposable endoscopes, laser lithotripsy accessories, and hydrophilic catheters.

Washington accounted for USD 0.17 billion in 2026, having grown from USD 0.12 billion in 2023, USD 0.14 billion in 2024, and USD 0.15 billion in 2025, and is expected to climb to USD 0.31 billion by 2032, exhibiting a 10.51% CAGR from 2027 to 2032. Washington’s healthcare landscape is anchored by major academic and regional providers such as UW Medicine and Providence. The state has embraced environmentally sustainable single-use programs, where manufacturers establish dedicated medical plastics reclamation and recycling streams. In Seattle and surrounding regional centers, urology clinics rely on pre-packaged disposable cystoscopy trays to maintain high diagnostic throughput.

Arizona generated USD 0.16 billion in 2026, moving from USD 0.11 billion in 2023, USD 0.13 billion in 2024, and USD 0.14 billion in 2025, and is slated to attain USD 0.30 billion by 2032, reflecting a rapid 11.08% CAGR from 2027 to 2032. Arizona’s demographic expansion is heavily driven by senior migration into the Phoenix metropolitan area, Scottsdale, and Tucson. The influx of older adults generates substantial clinical volume for benign prostatic hyperplasia management, pelvic floor reconstruction, bladder cancer surveillance, and chronic catheterization. The arid desert climate accelerates kidney stone formation, sustaining consistent surgical demand for single-use ureteroscopes and nitinol retrieval baskets across regional hospital networks.

Colorado registered USD 0.13 billion in 2026, having recorded USD 0.09 billion in 2023, USD 0.10 billion in 2024, and USD 0.12 billion in 2025, and is anticipated to achieve USD 0.24 billion by 2032, advancing at a CAGR of 10.86% from 2027 to 2032. Denver and the Front Range corridor support a robust network of ambulatory surgery centers and specialized urology groups, including UCHealth, that prioritize procedural efficiency and turnover velocity. The high proportion of privately insured, active patients drives demand for premium, compact hydrophilic intermittent catheters that offer discreet, touch-free self-catheterization.

Oregon, Utah, Nevada, and New Mexico collectively generated USD 0.13 billion in 2026, advancing from USD 0.10 billion in 2023, USD 0.10 billion in 2024, and USD 0.12 billion in 2025, and are projected to attain USD 0.22 billion by 2032, registering a CAGR of 9.15% from 2027 to 2032. In Utah, Intermountain Health operates as a benchmark for value-based care and clinical standardization, utilizing data-driven procurement models to validate the total cost savings of single-use ureteroscopes over reusable scopes. Across Nevada and New Mexico, rising population growth and limited specialized sterilization infrastructure in non-metropolitan facilities support the widespread adoption of factory-sterile disposable endourology supplies.

Midwest

The Midwest represents a highly stable, clinically mature, and volume-dense market for disposable urology devices, generating USD 1.05 billion in 2026, following historical figures of USD 0.81 billion in 2023, USD 0.88 billion in 2024, and USD 0.96 billion in 2025, and is forecast to expand at a CAGR of 9.30% to achieve USD 1.79 billion by 2032. The region is distinguished by renowned tertiary medical institutions, major health systems, an aging industrial and rural population, and substantial chronic urological disease prevalence. While overall population growth is moderate compared to the Sunbelt, the Midwest exhibits high rates of diabetes, cardiovascular comorbidities, and mobility-limiting neurological disorders that directly escalate the incidence of neurogenic bladder, urinary tract retention, and long-term catheter dependence. Consequently, the Midwest represents a cornerstone market for high-volume closed-system Foley trays and sterile intermittent catheters across inpatient, long-term care, and home health settings.

Illinois serves as the commercial epicenter of the Midwestern market, generating USD 0.26 billion in 2026, having recorded USD 0.20 billion in 2023, USD 0.22 billion in 2024, and USD 0.24 billion in 2025, and is anticipated to reach USD 0.44 billion by 2032, tracking an 9.15% CAGR from 2027 to 2032. Chicago supports prominent healthcare systems, including Northwestern Medicine, Rush University Medical Center, and the University of Chicago Medicine. These major academic facilities manage high-acuity urological oncology, complex reconstructive surgeries, and large-volume stone clinics. High surgical caseloads in urban Chicago, coupled with expanding ambulatory surgery networks in suburban Cook, DuPage, and Lake counties, drive large-scale institutional purchasing of single-use flexible cystoscopes, stone baskets, and disposable access sheaths.

Ohio represents another major market pillar, accounting for USD 0.24 billion in 2026, having expanded from USD 0.19 billion in 2023, USD 0.20 billion in 2024, and USD 0.22 billion in 2025, and is expected to climb to USD 0.41 billion by 2032, achieving a CAGR of 9.32% from 2027 to 2032. Ohio houses internationally recognized healthcare powerhouses, most notably the Cleveland Clinic, which sets national clinical benchmarks in urology and minimally invasive surgical protocols. Cleveland Clinic and other major health systems, such as OhioHealth and University Hospitals, have led rigorous health economic assessments demonstrating the infection-control and workflow advantages of single-use digital ureteroscopy. Furthermore, Ohio’s large industrial and post-acute care populations sustain high, recurring demand for silicone Foley catheter trays and hydrophilic intermittent catheters.

Michigan generated USD 0.19 billion in 2026, following historical marks of USD 0.15 billion in 2023, USD 0.16 billion in 2024, and USD 0.17 billion in 2025, and is projected to reach USD 0.32 billion by 2032, reflecting an 9.07% CAGR from 2027 to 2032. Michigan’s healthcare system, anchored by Corewell Health and Michigan Medicine, serves as a progressive proving ground for surgical quality initiatives. The Michigan Urological Surgery Improvement Collaborative (MUSIC) has actively evaluated surgical outcomes and complication rates in kidney stone treatments, driving standardized usage of safety-engineered guidewires, single-use access sheaths, and postoperative stents that minimize emergency department revisits.

Indiana accounted for USD 0.14 billion in 2026, having grown from USD 0.11 billion in 2023, USD 0.12 billion in 2024, and USD 0.13 billion in 2025, and is slated to attain USD 0.24 billion by 2032, advancing at a CAGR of 9.42% from 2027 to 2032. Indiana University Health operates one of the highest-volume endourology and kidney stone centers in North America, serving as a key driver of interventional disposable consumption. Indiana’s substantial medtech presence and well-established distribution logistics ensure rapid supply chain integration for hospital networks.

Wisconsin registered USD 0.11 billion in 2026, moving from USD 0.08 billion in 2023, USD 0.09 billion in 2024, and USD 0.10 billion in 2025, and is anticipated to achieve USD 0.19 billion by 2032, recording an 9.58% CAGR from 2027 to 2032. Health networks such as Advocate Aurora Health and UW Health maintain rigorous catheter-associated urinary tract infection prevention initiatives, driving the systematic replacement of legacy catheters with 100% silicone closed systems.

Minnesota, Missouri, Iowa, Kansas, Nebraska, and the Dakotas collectively generated USD 0.11 billion in 2026, having advanced from USD 0.08 billion in 2023, USD 0.09 billion in 2024, and USD 0.10 billion in 2025, and are projected to reach USD 0.19 billion by 2032, exhibiting a CAGR of 9.58% from 2027 to 2032. Minnesota is home to the Mayo Clinic in Rochester, a global beacon of urological excellence that shapes international clinical guidelines and evaluates cutting-edge single-use visualization and stone management platforms. Throughout rural agricultural regions in Iowa, Kansas, and the Dakotas, community hospitals face severe staffing shortages in sterile processing departments, leading clinical administrators to adopt single-use cystoscopes and pre-packaged procedural trays to maintain uninterrupted urological coverage.

Northeast

The Northeast represents a highly concentrated, clinically sophisticated, and value-dense market for disposable urology devices, generating USD 0.88 billion in 2026, building upon historical values of USD 0.68 billion in 2023, USD 0.73 billion in 2024, and USD 0.80 billion in 2025, and is projected to reach USD 1.46 billion by 2032, expanding at a CAGR of 8.81% from 2027 to 2032. The region is distinguished by the highest density of academic medical centers, tertiary urology referral networks, medical research institutions, and specialist physicians in the United States. While the overall incidence of kidney stone disease is lower than in the Southern Stone Belt, the Northeast exhibits an exceptionally high procedural intensity for urological oncology, complex reconstructive surgery, and pediatric urology. Stringent state healthcare department regulations and rigorous institutional infection control oversight have fostered an environment that actively embraces single-use technologies to eliminate hospital-acquired pathogens.

New York serves as the dominant anchor of the Northeastern market, accounting for USD 0.38 billion in 2026, having recorded USD 0.30 billion in 2023, USD 0.32 billion in 2024, and USD 0.35 billion in 2025, and is forecast to achieve USD 0.63 billion by 2032, expanding at a CAGR of 8.78% from 2027 to 2032. New York City and its surrounding metropolitan area support some of the most prominent medical institutions in the world, including Memorial Sloan Kettering Cancer Center, NewYork-Presbyterian, Mount Sinai Health System, and NYU Langone Health. Memorial Sloan Kettering’s high-volume bladder cancer surveillance programs have been instrumental in driving the transition toward single-use flexible cystoscopy, demonstrating that single-use scopes match the diagnostic sensitivity of reusable video towers while mitigating contamination risks during frequent surveillance procedures. Upstate New York health networks, such as Strong Memorial Hospital in Rochester and Albany Medical Center, utilize high volumes of single-use stone extraction kits and closed-system catheter kits across inpatient and outpatient channels.

Pennsylvania represents another major commercial cornerstone, generating USD 0.24 billion in 2026, having expanded from USD 0.19 billion in 2023, USD 0.20 billion in 2024, and USD 0.22 billion in 2025, and is expected to climb to USD 0.40 billion by 2032, reflecting an 8.89% CAGR from 2027 to 2032. The state’s healthcare landscape is anchored by vast integrated delivery networks, including the University of Pennsylvania Health System (Penn Medicine) and UPMC in Pittsburgh. UPMC operates as one of the largest integrated healthcare enterprises in the country, utilizing centralized enterprise resource planning and group contracting to standardize disposable urology consumables across dozens of hospitals and hundreds of outpatient facilities. Pennsylvania’s substantial elderly demographic in non-metropolitan counties also drives extensive recurring demand for sterile hydrophilic intermittent catheters and home continence supplies.

Massachusetts accounted for USD 0.15 billion in 2026, moving from USD 0.11 billion in 2023, USD 0.12 billion in 2024, and USD 0.13 billion in 2025, and is slated to attain USD 0.26 billion by 2032, registering a 9.61% CAGR from 2027 to 2032. Boston’s medical ecosystem, featuring Massachusetts General Hospital, Brigham and Women’s Hospital, and Beth Israel Deaconess Medical Center, serves as an influential national proving ground for medtech innovation. Massachusetts hospitals actively conduct health economic and clinical utility trials that validate the procedural economics of single-use ureteroscopes over traditional reusable platforms, accelerating adoption across the broader New England region.

New Jersey generated USD 0.11 billion in 2026, following historical marks of USD 0.08 billion in 2023, USD 0.09 billion in 2024, and USD 0.10 billion in 2025, and is projected to reach USD 0.17 billion by 2032, tracking a CAGR of 7.53% from 2027 to 2032. Major health systems such as RWJBarnabas Health and Hackensack Meridian Health maintain extensive networks of outpatient urology clinics and ambulatory surgery centers, driving steady consumption of disposable cystoscopes, biopsy needles, and double-J stents.

Connecticut, Rhode Island, Maine, New Hampshire, and Vermont collectively contributed USD 0.00 billion in 2026 (rounding to USD 0.00 billion when isolated under broad rounding, but precisely generating USD 0.04 billion in 2026, moving from USD 0.03 billion in 2023, USD 0.03 billion in 2024, and USD 0.03 billion in 2025, and reaching USD 0.06 billion by 2032, growing at a CAGR of 6.99% from 2027 to 2032). These Northern New England states feature advanced regional healthcare centers, such as Yale New Haven Health in Connecticut and Dartmouth Health in New Hampshire, alongside rural critical access hospitals. In rural Maine and Vermont, community facilities rely on single-use urological disposables to maintain complete surgical capabilities without maintaining costly scope reprocessing personnel on call.

Key Market Players

The U.S. Disposable Urology Devices competitive ecosystem is characterized by strategic consolidation in high-volume catheter lines and intense innovation-driven competition across single-use endoscopes, stone retrieval devices, and interventional lithotripsy disposables.

Some of the highly relevant key players operating in the U.S. disposable urology devices industry are:

Boston Scientific Corporation
Teleflex Incorporated
Coloplast Corp.
Becton, Dickinson and Company (BD)
Olympus Corporation of the Americas
Stryker Corporation
Ambu Inc.
Cook Medical LLC
Medtronic plc
ConvaTec Group Plc
Hollister Incorporated
Merit Medical Systems, Inc.
Richard Wolf Medical Instruments Corporation
Karl Storz Endoscopy-America, Inc.
Urotronic, Inc.

Boston Scientific Corporation maintains a preeminent leadership position across the interventional urology sector. The company’s comprehensive portfolio spans single-use digital flexible ureteroscopes, ureteral access sheaths, nitinol stone baskets, holmium and thulium laser fibers, and double-J ureteral stents. Boston Scientific leverages deep clinical relationships and bundled enterprise contracting, providing hospitals with complete endourology procedural kits that minimize supply chain overhead. Its continuous investments in chip-on-tip visualization and specialized suction capabilities reinforce its market-leading standing in kidney stone management and surgical urology.

Teleflex Incorporated competes forcefully across both acute interventional urology and patient drainage lines. Through its specialized urology and surgical divisions, Teleflex provides advanced single-use catheter systems, hydrophilic intermittent lines, access sheaths, and the UroLift system accessories for benign prostatic hyperplasia. The company’s strategic focus centers on minimizing mucosal trauma, expediting patient recovery, and enhancing procedural efficiency in both hospital operating rooms and ambulatory surgery centers.

Coloplast Corp. stands as a global titan in continence care and interventional urology. Its consumer-oriented and institutional product offerings include the SpeediCath family of pre-hydrated, ready-to-use hydrophilic intermittent catheters, which have set the clinical benchmark for reducing urethral friction and stricture formation. Coloplast also commands a robust interventional portfolio comprising single-use double-J stents, extraction baskets, guidewires, and access sheaths, capturing high recurring consumable volume across home health, long-term care, and surgical suites.

Becton, Dickinson and Company (BD) exerts commanding influence over institutional urinary drainage and hospital infection prevention. Through its legacy Bard urology portfolio, BD dominates the acute care closed-system Foley catheter market. The company’s antimicrobial and hydrogel-coated Foley catheter trays are engineered to address CMS catheter-associated urinary tract infection penalties, making BD a standard supply chain partner for thousands of U.S. acute care hospitals. BD also provides an extensive catalog of intermittent catheters, external collection devices, and specialized biopsy instruments.

Olympus Corporation of the Americas, historically synonymous with reusable endoscopic towers, has aggressively expanded into the single-use urology landscape. Recognizing the structural shift toward disposable visualization, Olympus has commercialized single-use flexible ureteroscopes and disposable cystoscopes alongside an expansive line of lithotripsy accessories, stone extraction devices, and ureteral stents. Olympus leverages its massive installed base of hospital video processors and surgical suites to cross-sell disposable scopes to surgical departments seeking hybrid equipment flexibility.

Stryker Corporation, through its endoscopy and surgical divisions, delivers specialized single-use visualization and fluid management systems tailored for outpatient surgical suites and hospital operating theaters. Stryker’s digital imaging platforms prioritize seamless integration with operating room connectivity infrastructure, high-definition visualization, and rapid turnaround times. Its procedural disposables catalog addresses both general and specialty urological interventions.

Ambu Inc. is the pioneer of dedicated single-use endoscopy and has captured substantial market share within disposable urology. Ambu’s single-use flexible cystoscope platforms have revolutionized office-based urology clinics and hospital consultation workflows by completely removing the capital, labor, and microbiological burdens of scope reprocessing. With continuous advancements in display interfaces and mechanical scope deflection, Ambu remains a fierce technology disruptor across diagnostic and therapeutic urology.

Cook Medical LLC maintains a venerated reputation in minimally invasive urological surgery. Cook’s disposable catalog includes precision-engineered nitinol stone extractors, bi-flex access sheaths, hydrophilic guidewires, percutaneous nephrostomy sets, and silicone double-J stents. Renowned for metallurgical and polymer engineering, Cook Medical’s products are heavily favored by endourologists managing complex stone morphology and delicate reconstructive cases.

Medtronic plc participates strategically across the urological landscape through its pelvic health and advanced surgical technologies. While heavily focused on sacral neuromodulation for overactive bladder and bowel incontinence, Medtronic manufactures high-quality disposable accessories, specialized surgical drainage products, and interventional tools that support complex pelvic floor and urological reconstructive procedures.

ConvaTec Group Plc is a prominent competitor in chronic continence management and wound therapeutics. Through its GentleCath portfolio, ConvaTec delivers advanced hydrophilic intermittent catheters featuring FeelClean technology, which integrates the hydrophilic property directly into the polymer matrix. This prevents residual coating sticky transfer to clothing or hands, enhancing patient adherence and satisfaction across home care and rehabilitation channels.

Hollister Incorporated commands substantial loyalty in the home continence and rehabilitation sectors. Hollister manufactures the VaPro family of no-touch hydrophilic intermittent catheters, which feature a sterile protective tip and sleeve that shield the catheter tube from bacterial contamination during insertion. Hollister’s emphasis on user-friendly packaging and touch-free delivery makes it a top choice for individuals with spinal cord injuries and neurogenic bladder.

Merit Medical Systems, Inc. specializes in interventional disposable accessories, offering an array of drainage catheters, guidewires, torque devices, inflation systems, and biopsy needles. Merit Medical’s focus on high-reliability, single-use vascular and urological access devices allows it to serve as a high-margin supply partner for interventional radiologists and urologists performing percutaneous nephrostomies and renal interventions.

Richard Wolf Medical Instruments Corporation and Karl Storz Endoscopy-America, Inc. represent prestigious endourology engineering leaders that have expanded their product matrices to include single-use visualization options, specialized access sheaths, disposable lithotripsy fibers, and stone extraction consumables. Both companies provide hybrid ecosystems that allow surgical departments to transition smoothly between reusable capital investments and single-use operational lines based on case acuity and infection risk profiles.

Urotronic, Inc. represents an agile, innovation-focused medical technology company pioneering drug-coated balloon technologies for urological indications. Its single-use Optilume drug-coated balloon catheter systems represent a major breakthrough in treating recurrent urethral strictures and benign prostatic hyperplasia, merging mechanical dilation with local paclitaxel delivery to prevent cellular proliferation and eliminate repeat surgical episodes.

Competitive advantage through 2032 will hinge on enterprise contracting strength, clinical evidence demonstrating CAUTI and sepsis reduction, sustainable polymer recycling programs, integrated digital imaging clarity, and the capacity to deliver procedure-ready, barcoded surgical kits that eliminate operational waste across hospital and ambulatory surgery supply chains.

Recent Developments

The U.S. disposable urology device ecosystem has experienced unprecedented commercial, clinical, and regulatory acceleration since 2024.

Regulatory agencies have intensified focus on cross-contamination risks associated with endoscope reprocessing. The Food and Drug Administration has issued successive safety communications and updated guidances advising healthcare providers to transition toward single-use visualization platforms whenever clinically feasible, particularly for high-volume diagnostic cystoscopy and ureteroscopic lithotripsy. This regulatory tailwind has prompted hospital risk management and infection control committees across the United States to accelerate their phase-out plans for aging flexible scope fleets, replacing them with single-use platforms to eliminate ethylene oxide exposure and bioburden liabilities.

Technological convergence between suction, pressure sensing, and disposable visualization has emerged as a dominant development. Medical device innovators have commercialized single-use digital ureteroscopes equipped with live intrarenal pressure monitoring sensors and integrated suction conduits. These platforms allow the surgical team to continuously evacuate stone debris and irrigation fluid during high-power laser dusting, maintaining intrarenal pressures safely below 30 millimeters of mercury. This innovation dramatically reduces the risk of postoperative pyelovenous backflow, bacteremia, and sepsis, setting a new clinical standard for kidney stone interventions in both inpatient and outpatient settings.

Mergers, acquisitions, and strategic partnerships have actively restructured the competitive landscape. Medical technology conglomerates have acquired specialized single-use visualization startups, drug-coated balloon developers, and advanced catheter coating firms to assemble comprehensive urology portfolios. Concurrently, major manufacturers have forged strategic alliances with third-party medical waste management enterprises to establish institutional take-back and closed-loop recycling programs. These initiatives address hospital environmental, social, and governance mandates by repurposing uncontaminated handle components and sterilizing plastics for industrial recycling, directly countering traditional criticisms of single-use device waste.

In the continence sector, clinical guidelines published by the American Urological Association and society recommendations have reinforced the primary role of single-use, touch-free hydrophilic intermittent catheters over reusable wash-and-dry alternatives for patients managing neurogenic lower urinary tract dysfunction. Clinical publications highlighting significant reductions in micro-trauma, hematuria, and secondary urinary tract infections among hydrophilic catheter cohorts have bolstered continuous Medicare Part B reimbursement justification, driving steady volume growth across durable medical equipment supply networks.

Hospital procurement dynamics have fundamentally adapted to persistent sterile processing department labor shortages. Following severe post-pandemic turnover in surgical processing technicians, healthcare networks across the South, Midwest, and West have struggled to maintain round-the-clock scope reprocessing capacity. Adopting disposable cystoscopes and single-use stone management trays has enabled hospital operating suites and ambulatory surgery centers to guarantee procedural capacity without risking delayed surgical starts or overtime staffing expenditures.

Finally, drug-device combination products have entered mainstream clinical adoption within disposable urology. The commercial scaling of single-use paclitaxel-coated dilation balloons for urethral stricture management has revolutionized outpatient stricture treatment. These disposable interventional platforms provide durable patency without requiring complex reconstructive urethroplasty, demonstrating how disposable devices can redefine therapeutic paradigms while shifting procedures into cost-effective outpatient environments.

Conclusion

The U.S. Disposable Urology Devices Market is positioned to expand from USD 5.12 billion in 2026 to approximately USD 8.96 billion by 2032, supported by a 9.78% CAGR from 2027 to 2032. Historical market progression from USD 3.85 billion in 2023 to USD 4.64 billion in 2025 demonstrates a sustained, structural conversion away from reusable, reprocessing-intensive hardware toward pristine, single-use clinical solutions across the entire urological care pathway.

The underlying growth thesis is supported by powerful clinical, economic, and demographic drivers. The relentless prevalence of urolithiasis throughout the American population, particularly across the Southern Stone Belt, guarantees steady surgical caseloads that consume single-use ureteroscopes, access sheaths, laser fibers, and double-J stents. Concurrently, an expanding geriatric demographic burdened by benign prostatic hyperplasia, urinary incontinence, bladder cancer, and neurogenic bladder ensures continuous demand for advanced hydrophilic intermittent catheters, closed-system Foley trays, and single-use diagnostic cystoscopy platforms.

Healthcare economics and infection control mandates have made disposable adoption an institutional imperative. With the Centers for Medicare and Medicaid Services enforcing severe financial penalties under the Hospital-Acquired Condition Reduction Program, health systems cannot afford the clinical or financial toll of catheter-associated urinary tract infections or endoscope-mediated cross-contamination. Single-use devices provide a complete sterilization guarantee, eliminate volatile scope repair expenses, bypass chronic sterile processing labor shortages, and accelerate procedural room turnover across hospital operating rooms and ambulatory surgery centers.

The most attractive commercial opportunities through 2032 will reside in disposable digital visualization, touch-free closed-system catheter kits, integrated suction ureteroscopy, advanced biomaterial stents that resist encrustation, and single-use drug-coated balloon delivery systems. Ambulatory surgery centers and outpatient urology clinics will continue to represent the fastest-growing customer segments, requiring compact, procedure-ready disposable packs that minimize physical footprint and administrative overhead.

Geographically, the South will maintain its commercial dominance in absolute revenue, driven by high population growth, an expansive Medicare demographic, and elevated kidney stone incidence. Texas and Florida will remain premier state markets for disposable urological purchasing. Concurrently, the West will chart the highest regional growth rate through 2032, propelled by progressive integrated health networks, massive ambulatory surgical investments, and rapid adoption of digital single-use platforms in California, Washington, and Arizona. The Midwest will provide a volume-dense, stable foundation anchored by major hospital networks managing chronic geriatric disease burdens, while the Northeast will remain a high-value epicenter for advanced urological oncology, academic clinical trials, and premium technology adoption.

For medical device manufacturers, clinical leadership, group purchasing organizations, and healthcare investors, the strategic mandate is clear. The commercial battleground has moved beyond selling isolated hardware or undifferentiated plastic consumables. Long-term market leadership belongs to enterprises that deliver comprehensive, clinically validated, and environmentally responsible disposable ecosystems that streamline clinical workflows, safeguard patient outcomes, protect hospital financial margins, and elevate the standard of urological care across the United States.